Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection

Thierry Lacaze-Masmonteil, Juergen Seidenberg, Ian Mitchell, Veerle Cossey, Martin Cihar, Michal Csader, Rienk Baarsma, Marques Valido, Paul F. Pollack, Jessie R. Groothuis, Karel Allegaert, Jacques Lombet, Dominique Haumont, Katleen Plaskie, H. Dele Davies, Reginald S. Sauve, Joanne M. Langley, Karel Liska, Patrick Andre, Pierre LequienNadine Kacet, Fabrice Lapeyre, Barbara Wickenburg-Ennen, Helga Nolte, Peter Andreas Harding, Sandra Ramos, Margarida Carolino, Antónia Marques

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Palivizumab reduces respiratory syncytial virus (RSV) hospitalisations in high-risk infants. Those with severe bronchopulmonary dysplasia may require two seasons of prophylaxis. There is concern that this humanised antibody might cause an adverse immune response in a second season of use. Objective: To evaluate and compare the occurrence of anti-palivizumab antibodies and clinical adverse events in subjects receiving monthly palivizumab injections for a first and second season, and to assess frequency and severity of RSV disease in the two groups. Design and Patients: Subjects aged ≤2 years at severe risk for RSV disease were designated as first season (no previous palivizumab exposure) or second season subjects (received palivizumab in previous RSV season). Palivizumab injections (15 mg/kg) were administered monthly for up to 5 months. Anti-palivizumab antibody titres and serum palivizumab concentrations were measured; adverse events were recorded. Results: No first (n = 71) or second (n = 63) season subjects experienced a significant anti-palivizumab antibody response (titre ≥1:80). Serum palivizumab concentrations were similar for the two groups. Nine (12.7%) first season and 8 (12.7%) second season subjects experienced one or more serious adverse events; most were respiratory and all were considered to be not or probably not related to palivizumab. No deaths occurred during the study. Conclusions: Monthly palivizumab injections were not associated with adverse immune responses or adverse events in young children receiving palivizumab for one or two seasons. Children receiving palivizumab for a second season did not experience more severe adverse events than those receiving it for the first time.

Original languageEnglish (US)
Pages (from-to)283-291
Number of pages9
JournalDrug Safety
Volume26
Issue number4
DOIs
StatePublished - Apr 3 2003

Fingerprint

Respiratory Syncytial Virus Infections
Viruses
Safety
Respiratory Syncytial Viruses
Anti-Idiotypic Antibodies
Virus Diseases
Palivizumab
Injections
Antibodies
Antibodies, Monoclonal, Humanized
Bronchopulmonary Dysplasia
Serum

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. / Lacaze-Masmonteil, Thierry; Seidenberg, Juergen; Mitchell, Ian; Cossey, Veerle; Cihar, Martin; Csader, Michal; Baarsma, Rienk; Valido, Marques; Pollack, Paul F.; Groothuis, Jessie R.; Allegaert, Karel; Lombet, Jacques; Haumont, Dominique; Plaskie, Katleen; Davies, H. Dele; Sauve, Reginald S.; Langley, Joanne M.; Liska, Karel; Andre, Patrick; Lequien, Pierre; Kacet, Nadine; Lapeyre, Fabrice; Wickenburg-Ennen, Barbara; Nolte, Helga; Harding, Peter Andreas; Ramos, Sandra; Carolino, Margarida; Marques, Antónia.

In: Drug Safety, Vol. 26, No. 4, 03.04.2003, p. 283-291.

Research output: Contribution to journalArticle

Lacaze-Masmonteil, T, Seidenberg, J, Mitchell, I, Cossey, V, Cihar, M, Csader, M, Baarsma, R, Valido, M, Pollack, PF, Groothuis, JR, Allegaert, K, Lombet, J, Haumont, D, Plaskie, K, Davies, HD, Sauve, RS, Langley, JM, Liska, K, Andre, P, Lequien, P, Kacet, N, Lapeyre, F, Wickenburg-Ennen, B, Nolte, H, Harding, PA, Ramos, S, Carolino, M & Marques, A 2003, 'Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection', Drug Safety, vol. 26, no. 4, pp. 283-291. https://doi.org/10.2165/00002018-200326040-00005
Lacaze-Masmonteil, Thierry ; Seidenberg, Juergen ; Mitchell, Ian ; Cossey, Veerle ; Cihar, Martin ; Csader, Michal ; Baarsma, Rienk ; Valido, Marques ; Pollack, Paul F. ; Groothuis, Jessie R. ; Allegaert, Karel ; Lombet, Jacques ; Haumont, Dominique ; Plaskie, Katleen ; Davies, H. Dele ; Sauve, Reginald S. ; Langley, Joanne M. ; Liska, Karel ; Andre, Patrick ; Lequien, Pierre ; Kacet, Nadine ; Lapeyre, Fabrice ; Wickenburg-Ennen, Barbara ; Nolte, Helga ; Harding, Peter Andreas ; Ramos, Sandra ; Carolino, Margarida ; Marques, Antónia. / Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. In: Drug Safety. 2003 ; Vol. 26, No. 4. pp. 283-291.
@article{59f0a972e7fd4eb593ce32eeecfc08b6,
title = "Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection",
abstract = "Background: Palivizumab reduces respiratory syncytial virus (RSV) hospitalisations in high-risk infants. Those with severe bronchopulmonary dysplasia may require two seasons of prophylaxis. There is concern that this humanised antibody might cause an adverse immune response in a second season of use. Objective: To evaluate and compare the occurrence of anti-palivizumab antibodies and clinical adverse events in subjects receiving monthly palivizumab injections for a first and second season, and to assess frequency and severity of RSV disease in the two groups. Design and Patients: Subjects aged ≤2 years at severe risk for RSV disease were designated as first season (no previous palivizumab exposure) or second season subjects (received palivizumab in previous RSV season). Palivizumab injections (15 mg/kg) were administered monthly for up to 5 months. Anti-palivizumab antibody titres and serum palivizumab concentrations were measured; adverse events were recorded. Results: No first (n = 71) or second (n = 63) season subjects experienced a significant anti-palivizumab antibody response (titre ≥1:80). Serum palivizumab concentrations were similar for the two groups. Nine (12.7{\%}) first season and 8 (12.7{\%}) second season subjects experienced one or more serious adverse events; most were respiratory and all were considered to be not or probably not related to palivizumab. No deaths occurred during the study. Conclusions: Monthly palivizumab injections were not associated with adverse immune responses or adverse events in young children receiving palivizumab for one or two seasons. Children receiving palivizumab for a second season did not experience more severe adverse events than those receiving it for the first time.",
author = "Thierry Lacaze-Masmonteil and Juergen Seidenberg and Ian Mitchell and Veerle Cossey and Martin Cihar and Michal Csader and Rienk Baarsma and Marques Valido and Pollack, {Paul F.} and Groothuis, {Jessie R.} and Karel Allegaert and Jacques Lombet and Dominique Haumont and Katleen Plaskie and Davies, {H. Dele} and Sauve, {Reginald S.} and Langley, {Joanne M.} and Karel Liska and Patrick Andre and Pierre Lequien and Nadine Kacet and Fabrice Lapeyre and Barbara Wickenburg-Ennen and Helga Nolte and Harding, {Peter Andreas} and Sandra Ramos and Margarida Carolino and Ant{\'o}nia Marques",
year = "2003",
month = "4",
day = "3",
doi = "10.2165/00002018-200326040-00005",
language = "English (US)",
volume = "26",
pages = "283--291",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection

AU - Lacaze-Masmonteil, Thierry

AU - Seidenberg, Juergen

AU - Mitchell, Ian

AU - Cossey, Veerle

AU - Cihar, Martin

AU - Csader, Michal

AU - Baarsma, Rienk

AU - Valido, Marques

AU - Pollack, Paul F.

AU - Groothuis, Jessie R.

AU - Allegaert, Karel

AU - Lombet, Jacques

AU - Haumont, Dominique

AU - Plaskie, Katleen

AU - Davies, H. Dele

AU - Sauve, Reginald S.

AU - Langley, Joanne M.

AU - Liska, Karel

AU - Andre, Patrick

AU - Lequien, Pierre

AU - Kacet, Nadine

AU - Lapeyre, Fabrice

AU - Wickenburg-Ennen, Barbara

AU - Nolte, Helga

AU - Harding, Peter Andreas

AU - Ramos, Sandra

AU - Carolino, Margarida

AU - Marques, Antónia

PY - 2003/4/3

Y1 - 2003/4/3

N2 - Background: Palivizumab reduces respiratory syncytial virus (RSV) hospitalisations in high-risk infants. Those with severe bronchopulmonary dysplasia may require two seasons of prophylaxis. There is concern that this humanised antibody might cause an adverse immune response in a second season of use. Objective: To evaluate and compare the occurrence of anti-palivizumab antibodies and clinical adverse events in subjects receiving monthly palivizumab injections for a first and second season, and to assess frequency and severity of RSV disease in the two groups. Design and Patients: Subjects aged ≤2 years at severe risk for RSV disease were designated as first season (no previous palivizumab exposure) or second season subjects (received palivizumab in previous RSV season). Palivizumab injections (15 mg/kg) were administered monthly for up to 5 months. Anti-palivizumab antibody titres and serum palivizumab concentrations were measured; adverse events were recorded. Results: No first (n = 71) or second (n = 63) season subjects experienced a significant anti-palivizumab antibody response (titre ≥1:80). Serum palivizumab concentrations were similar for the two groups. Nine (12.7%) first season and 8 (12.7%) second season subjects experienced one or more serious adverse events; most were respiratory and all were considered to be not or probably not related to palivizumab. No deaths occurred during the study. Conclusions: Monthly palivizumab injections were not associated with adverse immune responses or adverse events in young children receiving palivizumab for one or two seasons. Children receiving palivizumab for a second season did not experience more severe adverse events than those receiving it for the first time.

AB - Background: Palivizumab reduces respiratory syncytial virus (RSV) hospitalisations in high-risk infants. Those with severe bronchopulmonary dysplasia may require two seasons of prophylaxis. There is concern that this humanised antibody might cause an adverse immune response in a second season of use. Objective: To evaluate and compare the occurrence of anti-palivizumab antibodies and clinical adverse events in subjects receiving monthly palivizumab injections for a first and second season, and to assess frequency and severity of RSV disease in the two groups. Design and Patients: Subjects aged ≤2 years at severe risk for RSV disease were designated as first season (no previous palivizumab exposure) or second season subjects (received palivizumab in previous RSV season). Palivizumab injections (15 mg/kg) were administered monthly for up to 5 months. Anti-palivizumab antibody titres and serum palivizumab concentrations were measured; adverse events were recorded. Results: No first (n = 71) or second (n = 63) season subjects experienced a significant anti-palivizumab antibody response (titre ≥1:80). Serum palivizumab concentrations were similar for the two groups. Nine (12.7%) first season and 8 (12.7%) second season subjects experienced one or more serious adverse events; most were respiratory and all were considered to be not or probably not related to palivizumab. No deaths occurred during the study. Conclusions: Monthly palivizumab injections were not associated with adverse immune responses or adverse events in young children receiving palivizumab for one or two seasons. Children receiving palivizumab for a second season did not experience more severe adverse events than those receiving it for the first time.

UR - http://www.scopus.com/inward/record.url?scp=0037232387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037232387&partnerID=8YFLogxK

U2 - 10.2165/00002018-200326040-00005

DO - 10.2165/00002018-200326040-00005

M3 - Article

C2 - 12608889

AN - SCOPUS:0037232387

VL - 26

SP - 283

EP - 291

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 4

ER -